How do combined lipid and anti-inflammatory therapies work for coronary atherosclerosis?

Coronary atherosclerosis is a chronic disease driven by both lipid retention and immune system responses. While lowering LDL cholesterol is essential, it does not eliminate all risk because inflammation continues to damage blood vessels. Combined therapy addresses both the lipid buildup and the inflammatory process to better prevent heart attacks and strokes.

What the research says

Potent lipid-lowering therapies reduce major adverse cardiovascular events by clearing arterial retention of apolipoprotein B-containing lipoproteins ²⁴. However, substantial residual risk often remains even after intensive LDL-C lowering, which highlights the need to target other factors ²⁴.

Targeted anti-inflammatory therapies, such as low-dose colchicine and IL-1β inhibition, reduce recurrent events without altering LDL-C levels ²⁴. This proves that inflammation is a separate, modifiable driver of coronary risk ²⁴. Studies show that colchicine can reduce total plaque burden in patients with stable coronary artery disease ³.

The two processes are linked across the entire disease process, from initial vessel activation to plaque rupture ²⁴. Chronic inflammation modifies the lipoprotein profile toward a pro-oxidant state, characterized by dysfunctional HDL and elevated oxidized LDL ¹. This inflammatory environment amplifies the damage caused by lipids, making combined treatment necessary to fully control the disease ¹².

What to ask your doctor

• How do my current lipid and inflammation levels interact to affect my heart risk?
• Is low-dose colchicine an appropriate option for me to reduce residual inflammatory risk?
• Which additional lipid metrics, such as apolipoprotein B or lipoprotein(a), should we measure to guide my treatment?
• What is the best way to combine lipid-lowering drugs with anti-inflammatory therapy for my specific condition?